The OlympiA trial is being discussed on social media a lot. It’s been presented at #ASCO21 and the paper has come out in @NEJM (along with appendices). Since PROfound, I’ve approached Olaparib trials with a degree of healthy skepticism. But this seems promising. 
Main problems are:
- Interim analysis at only 2.5y follow up, so don’t jump to conclusions yet. Need to know whether olaparib really increases cure rate, or just delays recurrence.
- No comparison against adjuvant cape (CREATE-X) which is current SoC.
- Very expensive treatment!
- Interim analysis at only 2.5y follow up, so don’t jump to conclusions yet. Need to know whether olaparib really increases cure rate, or just delays recurrence.
- No comparison against adjuvant cape (CREATE-X) which is current SoC.
- Very expensive treatment!
This is too early, right?
• • •
Missing some Tweet in this thread? You can try to
force a refresh
